{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:02:31Z","timestamp":1789390951335,"version":"build-2803163510"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Osteosarcoma is the most common primary malignant bone tumor of children and adolescents. Multiagent neoadjuvant chemotherapy once improved survival substantially, but outcomes have since plateaued. Delivering immunotherapy before surgery is attractive because the primary tumor, the tumor immune microenvironment (TIME), and the tumor-draining lymph nodes (TDLNs) remain intact. This setting may allow the TIME to be reconfigured while antigen sampling and T-cell priming are still possible. It does not, however, make the tumor a vaccine, nor does it imply that expanded tumor-infiltrating lymphocytes are tumor specific. Any benefit is instead likely to depend on antigen quality, human leukocyte antigen (HLA)-mediated presentation, the availability of tumor-reactive T-cell clones, and the reversibility of local immunosuppression. Translation remains constrained by a low but heterogeneous mutational burden, a myeloid-dominated microenvironment, and the absence of validated selection biomarkers. Preoperative treatment must also preserve its established non-immunological goals, namely downstaging to enable limb salvage and control of micrometastatic disease. We therefore examine the biological rationale, the current evidence, and the surgical, radiological, and pathological barriers to translation. We additionally consider how structural genomic instability constrains antigen availability and presentation, and how natural killer cell-directed strategies may inform barrier-matched design. On this basis we propose a barrier-matched development framework in which pathological response, spatial multi-omics, and molecular clearance jointly define success.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1837053","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:02:36Z","timestamp":1789387356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating the immunosuppressive abyss: current hurdles and innovative breakthroughs in neoadjuvant immunotherapy for osteosarcoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Guanghao","family":"Chen","sequence":"first","affiliation":[{"name":"The Second Hospital of Jiaxing, Department of Orthopaedics, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Hu","sequence":"additional","affiliation":[{"name":"The Second Hospital of Jiaxing, Department of Orthopaedics, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkun","family":"Li","sequence":"additional","affiliation":[{"name":"The Third Department of Medical Oncology, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunpeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Surgery II, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Chen","sequence":"additional","affiliation":[{"name":"The Second Hospital of Jiaxing, Department of Orthopaedics, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhao","family":"Xu","sequence":"additional","affiliation":[{"name":"The Second Hospital of Jiaxing, Department of Orthopaedics, The Second Affiliated Hospital of Jiaxing University","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115876","article-title":"Amino acid transporter SLC7A11 functions in ferroptosis regulation and immune microenvironment in osteosarcoma","volume":"168","author":"Jia","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002324","article-title":"Osteosarcoma: current insights and advances","volume":"6","author":"Brar","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198606193142502","article-title":"The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity","volume":"314","author":"Link","year":"1986","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00003086-199109000-00003","article-title":"Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study","volume":"270","author":"Link","year":"1991","journal-title":"Clin Orthop Relat Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq276","article-title":"Osteosarcoma","volume":"21","author":"Ritter","year":"2010","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21724","article-title":"Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution","volume":"106","author":"Bacci","year":"2006","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3390\/biomedicines13030664","article-title":"Digging through the complexities of immunological approaches in emerging osteosarcoma therapeutics: A comprehensive narrative review with updated clinical trials","volume":"13","author":"Sergi","year":"2025","journal-title":"Biomedicines"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30270-4","article-title":"Maximum benefit of chemotherapy for osteosarcoma achieved-what are the next steps","volume":"17","author":"Kleinerman","year":"2016","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.132","article-title":"Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols","volume":"21","author":"Kager","year":"2003","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-023-00803-9","article-title":"Advances in osteosarcoma","volume":"21","author":"Panez-Toro","year":"2023","journal-title":"Curr Osteoporos Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00943-6","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14398","article-title":"Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma","volume":"111","author":"Deng","year":"2020","journal-title":"Cancer Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.709210","article-title":"Single-cell transcriptomics reveals the complexity of the tumor microenvironment of treatment-naive osteosarcoma","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00317.x","article-title":"Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5","volume":"97","author":"Tsukahara","year":"2006","journal-title":"Cancer Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","article-title":"Immuno-genomic landscape of osteosarcoma","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.595527","article-title":"The clinical implications of tumor mutational burden in osteosarcoma","volume":"10","author":"Xie","year":"2020","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.3390\/cancers13236075","article-title":"Tumor-infiltrating lymphocytes and cancer markers in osteosarcoma: Influence on patient survival","volume":"13","author":"Casanova","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.871076","article-title":"Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality","volume":"13","author":"Yu","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-021-00598-w","article-title":"The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications","volume":"44","author":"Huang","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.586580","article-title":"Macrophages in osteosarcoma immune microenvironment: Implications for immunotherapy","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor Pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-060619-023155","article-title":"Inhibition of the adenosine pathway to potentiate cancer immunotherapy: Potential for combinatorial approaches","volume":"72","author":"Thompson","year":"2021","journal-title":"Annu Rev Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02876-w","article-title":"Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial","volume":"70","author":"Boye","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1824","article-title":"Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab","volume":"26","author":"Keung","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2519","article-title":"Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma","volume":"30","author":"Movva","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e000798","DOI":"10.1136\/jitc-2020-000798","article-title":"Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial","volume":"8","author":"Xie","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70206","article-title":"Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial","volume":"13","author":"Tang","year":"2024","journal-title":"Cancer Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01287-7","article-title":"Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors","volume":"40","author":"Shimizu","year":"2022","journal-title":"Invest New Drugs"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2026.109452","article-title":"Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies","volume":"217","author":"Burotto","year":"2026","journal-title":"Lung Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16284-8","article-title":"Association of neoadjuvant immunotherapy with postoperative major morbidity after oncologic surgery","volume":"31","author":"Habib","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2026.111403","article-title":"Surgical complications after therapeutic lymph node dissection in stage III-IV melanoma: impact of neoadjuvant immunotherapy","volume":"52","author":"Lytchier","year":"2026","journal-title":"Eur J Surg Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","article-title":"Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial","volume":"30","author":"Kim","year":"2024","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.063","article-title":"Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)","volume":"23","author":"Kempf-Bielack","year":"2005","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/03008916211053048","article-title":"Lung metastasectomy for osteosarcoma in children, adolescents, and young adults: proof of permanent cure","volume":"109","author":"Pastorino","year":"2023","journal-title":"Tumori"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.775761","article-title":"Improving immunotherapy efficacy in soft-tissue sarcomas: A biomarker driven and histotype tailored review","volume":"12","author":"Roulleaux Dugage","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41571-024-00969-w","article-title":"T cell dynamics with neoadjuvant immunotherapy in head and neck cancer","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e010173","DOI":"10.1136\/jitc-2024-010173","article-title":"Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"13","author":"Chung","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.678127","article-title":"B cell orchestration of anti-tumor immune responses: a matter of cell localization and communication","volume":"9","author":"Kinker","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.489","article-title":"Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm (2020)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01821-3","article-title":"Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort","volume":"28","author":"Italiano","year":"2022","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.03.003","article-title":"Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma","volume":"7","author":"Chen","year":"2014","journal-title":"Cell Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15936","article-title":"Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma","volume":"8","author":"Behjati","year":"2017","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0387","article-title":"Metastasis and immune evasion from extracellular cGAMP hydrolysis","volume":"11","author":"Li","year":"2021","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","first-page":"eaaf8399","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e002568","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/BPB.0000000000001360","article-title":"Mid-term complication rate after limb salvage for pediatric bone sarcomas","author":"Colello","year":"2026","journal-title":"J Pediatr Orthop B"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/CORR.0000000000002687","article-title":"Are pathologic fractures in patients with osteosarcoma associated with worse survival outcomes? A systematic review and meta-analysis","volume":"481","author":"Gonzalez","year":"2023","journal-title":"Clin Orthop Relat Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00262-026-04433-9","article-title":"Optimizing the clinical assessment of pseudoprogression in patients with solid tumors treated with checkpoint inhibitors: a systematic literature review and meta-analysis of associated features","volume":"75","author":"Fountoukidis","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2344-8","article-title":"(1)(8)F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma","volume":"40","author":"Kong","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.063602","article-title":"Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI","volume":"50","author":"Cheon","year":"2009","journal-title":"J Nucl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102697","article-title":"Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma","volume":"73","author":"Fu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B68","doi-asserted-by":"publisher","first-page":"29","DOI":"10.32604\/or.2026.078833","article-title":"Circulating tumor DNA and microRNA-based liquid biopsy for longitudinal treatment monitoring and recurrence prediction in pediatric sarcomas: a prospective cohort study","volume":"34","author":"Kurdi","year":"2026","journal-title":"Oncol Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24268","article-title":"Detection of circulating tumor DNA in patients with osteosarcoma","volume":"9","author":"Barris","year":"2018","journal-title":"Oncotarget"},{"key":"B70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.1997.15.1.76","article-title":"Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group","volume":"15","author":"Provisor","year":"1997","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.24.4016","article-title":"Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli\/osteosarcoma-2 protocol: an updated report","volume":"18","author":"Bacci","year":"2000","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.018","article-title":"Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort","volume":"37","author":"Deutsch","year":"2026","journal-title":"Ann Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200845","article-title":"p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death","volume":"32","author":"Demiya","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1186\/s12885-025-14542-w","article-title":"Immunotherapy combined with radiotherapy in the treatment of lung cancer: a meta-analysis of therapeutic effectiveness, safety considerations, and abscopal effect","volume":"25","author":"Gao","year":"2025","journal-title":"BMC Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"Oncoimmunology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1539396","article-title":"Manipulating the cGAS-STING axis: advancing innovative strategies for osteosarcoma therapeutics","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403538","article-title":"Make it STING: nanotechnological approaches for activating cGAS\/STING as an immunomodulatory node in osteosarcoma","volume":"15","author":"O'Donoghue","year":"2024","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16514","article-title":"Irreversible electroporation combined with dendritic cell-based vaccines for the treatment of osteosarcoma","volume":"43","author":"Sun","year":"2023","journal-title":"Anticancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221124696","article-title":"Current status and prospects of clinical treatment of osteosarcoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.02.023","article-title":"Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2","volume":"33","author":"Mason","year":"2025","journal-title":"Mol Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30583","article-title":"Children's Oncology Group's 2023 blueprint for research: Bone tumors","author":"Reed","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.3390\/cancers13246229","article-title":"Cancer therapy targeting CD47\/SIRPalpha","volume":"13","author":"Dizman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/abt\/tby006","article-title":"Insights into CD47\/SIRPalpha axis-targeting tumor immunotherapy","volume":"1","author":"Zhang","year":"2018","journal-title":"Antib Ther"},{"key":"B86","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.34172\/bi.30424","article-title":"Targeting hypoxia-inducible factor 1 alpha augments synergistic effects of chemo\/immunotherapy via modulating tumor microenvironment in a breast cancer mouse model","volume":"15","author":"Rashid","year":"2025","journal-title":"Bioimpacts"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00262-024-03642-4","article-title":"Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 co-expression on functional activity","volume":"73","author":"Cao","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/bioengineering12121344","article-title":"Exploiting B7-H3: molecular insights and immunotherapeutic strategies for osteosarcoma","volume":"12","author":"Xie","year":"2025","journal-title":"Bioengineering (Basel)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-024-01641-7","article-title":"Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells","volume":"17","author":"Pezzella","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791206","article-title":"Enhancing natural killer cell targeting of pediatric sarcoma","volume":"12","author":"Omer","year":"2021","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1316","article-title":"Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition","volume":"70","author":"Fine","year":"2010","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3892\/or_00001026","article-title":"Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA\/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity","volume":"24","author":"Yamanegi","year":"2010","journal-title":"Oncol Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e008755","DOI":"10.1136\/jitc-2023-008755","article-title":"CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma","volume":"13","author":"Cho","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.05.035","article-title":"Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: a report from the Children's Oncology Group","volume":"172","author":"Hingorani","year":"2022","journal-title":"Eur J Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1640645","article-title":"Deciphering spatially confined immune evasion niches in osteosarcoma with 3-D spatial transcriptomics: a literature review","volume":"15","author":"Qiu","year":"2025","journal-title":"Front Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3892\/ijmm.2025.5533","article-title":"Harnessing multi-omics to revolutionize understanding and management of osteosarcoma: a pathway to precision medicine (review)","volume":"55","author":"Chen","year":"2025","journal-title":"Int J Mol Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0635","article-title":"Spatial profiling identifies tumor-associated stroma enrichment and MIF as potential immunotherapy targets in primary Ewing sarcomas","volume":"31","author":"Kuo","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-024-01619-5","article-title":"Correction: a single-cell and spatially resolved atlas of human osteosarcomas","volume":"17","author":"Zheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-3723","article-title":"Spatial profiling identifies regionally distinct microenvironments and targetable immunosuppressive mechanisms in pediatric osteosarcoma pulmonary metastases","volume":"85","author":"Eigenbrood","year":"2025","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"8294","DOI":"10.1038\/s41467-026-74603-x","article-title":"Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markers","volume":"17","author":"Moquin-Beaudry","year":"2026","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"key":"B107","doi-asserted-by":"publisher","first-page":"11179","DOI":"10.1038\/s41598-025-85149-1","article-title":"Improved gated recurrent unit-based osteosarcoma prediction on histology images: a meta-heuristic-oriented optimization concept","volume":"15","author":"Prabakaran","year":"2025","journal-title":"Sci Rep"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.577","article-title":"Neoadjuvant immunotherapy: new horizon for lymph node preservation","volume":"5","author":"Zhong","year":"2024","journal-title":"MedComm (2020)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1837053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:02:38Z","timestamp":1789387358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1837053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":108,"alternative-id":["10.3389\/fimmu.2026.1837053"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1837053","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1837053"}}